Abstract
At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Current Drug Targets
Title: PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Volume: 8 Issue: 9
Author(s): Douglas E. Vaughan, Bart M. De Taeye and Mesut Eren
Affiliation:
Keywords: Plasminogen activator inhibitor-1 (PAI-1), fibrinolysis, thrombosis, arteriosclerosis
Abstract: At present, thrombolytic agents represent the only direct way of augmenting fibrinolytic activity in humans. While these agents are proven to be efficacious in the treatment of acute thrombotic events, they are not a viable option for long-term administration. There are numerous drugs available that indirectly to increase fibrinolytic activity by reducing plasma levels of plasminogen activator inhibitor-1 (PAI-1), including ACE inhibitors, insulin-sensitizing agents, and hormone replacement therapy in women. At present, efforts are underway to develop and test synthetic, selective PAI-1 antagonists. The potential applications of PAI-1 antagonists include thrombotic disorders (arterial and venous), amyloidosis, obesity, polycystic ovarian syndrome, and perhaps even type 2 diabetes mellitus. The availability of specific PAI-1 antagonists promises to expand the limits of understanding the role the fibrinolytic system plays in human disease and break through the current confines of therapeutic options that can effectively restore and augment the activity of the fibrinolytic system.
Export Options
About this article
Cite this article as:
Vaughan E. Douglas, De Taeye M. Bart and Eren Mesut, PAI-1 Antagonists: Predictable Indications and Unconventional Applications, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662364
DOI https://dx.doi.org/10.2174/138945007781662364 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ageing and Nutritional Therapy Adherence in Type 2 Diabetes
Current Diabetes Reviews Selective Adsorption of Nitrate by a Macroporous Acrylic Anion Exchange Resin: Effect of the Competing Anions
Current Environmental Engineering Effects of Imidazolic Agonism on Blood Pressure, Sympathetic Activity, Left Ventricular Hypertrophy and Insulin Resistance
Current Hypertension Reviews Adverse Drug Reactions Amongst Adult Patients Admitted in Lagos State University Teaching Hospital Lagos, Nigeria
Current Drug Safety The Effects of Insulin and Insulin-Like Growth Factors on Tumor Vascularization: New Insights of Insulin-Like Growth Factor Family in Cancer
Current Medicinal Chemistry Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Gender Disparities on Access to Care and Coronary Disease Management
Current Pharmaceutical Design Assessment of Prescription Pattern in Asthma Therapy at Shamli Hospitals
Reviews on Recent Clinical Trials Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Effects of Probiotics on Diabetic Nephropathy: A Systematic Review
Current Clinical Pharmacology ROS Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?
Mini-Reviews in Medicinal Chemistry Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Oxidative Stress and the JNK Pathway are Involved in the Development of Type 1 and Type 2 Diabetes
Current Molecular Medicine EHDA Spraying: A Multi-Material Nano-Engineering Route
Current Pharmaceutical Design Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Rebalancing the Oral Microbiota as an Efficient Tool in Endocrine, Metabolic and Immune Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design